JP5576591B2 - α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 - Google Patents

α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 Download PDF

Info

Publication number
JP5576591B2
JP5576591B2 JP2007500529A JP2007500529A JP5576591B2 JP 5576591 B2 JP5576591 B2 JP 5576591B2 JP 2007500529 A JP2007500529 A JP 2007500529A JP 2007500529 A JP2007500529 A JP 2007500529A JP 5576591 B2 JP5576591 B2 JP 5576591B2
Authority
JP
Japan
Prior art keywords
day
cancer
ftd
administration
trifluorothymidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2007500529A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2006080327A1 (ja
Inventor
智博 江村
明 三田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5576591(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Priority to JP2007500529A priority Critical patent/JP5576591B2/ja
Publication of JPWO2006080327A1 publication Critical patent/JPWO2006080327A1/ja
Application granted granted Critical
Publication of JP5576591B2 publication Critical patent/JP5576591B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2007500529A 2005-01-26 2006-01-25 α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 Expired - Lifetime JP5576591B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007500529A JP5576591B2 (ja) 2005-01-26 2006-01-25 α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
US11/042,059 2005-01-26
JP2005165156 2005-06-06
JP2005165156 2005-06-06
JP2007500529A JP5576591B2 (ja) 2005-01-26 2006-01-25 α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤
PCT/JP2006/301097 WO2006080327A1 (ja) 2005-01-26 2006-01-25 α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Publications (2)

Publication Number Publication Date
JPWO2006080327A1 JPWO2006080327A1 (ja) 2008-06-19
JP5576591B2 true JP5576591B2 (ja) 2014-08-20

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007500529A Expired - Lifetime JP5576591B2 (ja) 2005-01-26 2006-01-25 α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Country Status (21)

Country Link
EP (1) EP1849470B2 (OSRAM)
JP (1) JP5576591B2 (OSRAM)
KR (1) KR101468216B1 (OSRAM)
AU (1) AU2006209547C1 (OSRAM)
BE (1) BE2017C028I2 (OSRAM)
CA (1) CA2594713A1 (OSRAM)
CY (2) CY2017029I2 (OSRAM)
DK (1) DK1849470T4 (OSRAM)
ES (1) ES2630002T5 (OSRAM)
FI (1) FI1849470T4 (OSRAM)
FR (1) FR17C1028I2 (OSRAM)
HU (2) HUE033306T2 (OSRAM)
LT (2) LT1849470T (OSRAM)
LU (1) LUC00036I2 (OSRAM)
NL (1) NL300889I2 (OSRAM)
PL (1) PL1849470T5 (OSRAM)
PT (1) PT1849470T (OSRAM)
RU (1) RU2394581C2 (OSRAM)
SI (1) SI1849470T2 (OSRAM)
TW (1) TWI362265B (OSRAM)
WO (1) WO2006080327A1 (OSRAM)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
PT1849470T (pt) 2005-01-26 2017-09-22 Taiho Pharmaceutical Co Ltd Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US8536188B2 (en) 2007-04-25 2013-09-17 Cyclacel Limited Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine
CN102014877B (zh) 2008-01-25 2017-06-06 格吕伦塔尔有限公司 药物剂型
PL2273983T3 (pl) 2008-05-09 2017-01-31 Grünenthal GmbH Sposób wytwarzania pośredniego preparatu proszkowego i końcowej stałej postaci dawkowania z zastosowaniem etapu zestalania rozpyłowego
JP2011520845A (ja) * 2008-05-15 2011-07-21 カソリック ユニヴェルシテイト ルーヴェン，ケー．ユー． ルーヴェン アール アンド ディー 抗癌剤の組合せによる治療
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
JP2012533585A (ja) 2009-07-22 2012-12-27 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 酸化感受性オピオイドのための不正使用防止剤形
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
NZ608865A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising an anionic polymer
PT2736497T (pt) 2011-07-29 2017-11-30 Gruenenthal Gmbh Comprimido resistente a adulteração proporcionando libertação imediata de fármaco
MX348491B (es) 2011-07-29 2017-06-15 Gruenenthal Gmbh Tableta a prueba de manipulacion que proporciona liberacion inmediata de fármaco.
US9371380B2 (en) * 2011-08-16 2016-06-21 Taiho Pharmaceutical Co., Ltd. Antitumor agent and therapeutic effect prediction method for patients with KRAS-mutated colorectal cancer
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
JP6030119B2 (ja) 2012-03-14 2016-11-24 日清ファルマ株式会社 含硫アミノ酸含有組成物
ES2692944T3 (es) 2012-04-18 2018-12-05 Grünenthal GmbH Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
KR20150009540A (ko) 2012-05-16 2015-01-26 노파르티스 아게 Pi-3 키나제 억제제에 대한 투여 요법
HUE041687T2 (hu) * 2013-03-27 2019-05-28 Taiho Pharmaceutical Co Ltd Antitumor szer, amely tartalmaz kis dózisú irinotekan-hidroklorid-hidrát-ot
JP5976923B2 (ja) * 2013-03-27 2016-08-24 大鵬薬品工業株式会社 イリノテカン塩酸塩水和物を含有する抗腫瘍剤
JP6312660B2 (ja) * 2013-05-17 2018-04-18 大鵬薬品工業株式会社 Ｔｋ１タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法
EP3003283A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
RS64243B1 (sr) 2013-09-06 2023-06-30 Taiho Pharmaceutical Co Ltd Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
JP6871868B2 (ja) * 2016-01-08 2021-05-19 大鵬薬品工業株式会社 免疫調節剤を含有する抗腫瘍剤及び抗腫瘍効果増強剤
KR102412690B1 (ko) 2016-02-05 2022-06-23 다이호야쿠힌고교 가부시키가이샤 중증 신장 기능 장애를 갖는 암 환자에 대한 치료 방법
EP3730935A4 (en) 2017-12-22 2022-02-23 Taiho Pharmaceutical Co., Ltd. METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
WO2026019875A1 (en) * 2024-07-17 2026-01-22 Jnd Therapeutics, Inc. Methods and formulations for treatment of liver cancer using trifluridine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227726B1 (en) * 1995-03-29 2012-01-30 Taiho Pharmaceutical Co Ltd Uracyl-derivatives and antitumor effect potentiator and antitumor agent containing the same
DK0884051T3 (da) * 1996-09-24 2005-01-24 Taiho Pharmaceutical Co Ltd Cancröse metastaseinhibitorer indeholdende uracilderivater
PT1849470T (pt) 2005-01-26 2017-09-22 Taiho Pharmaceutical Co Ltd Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6011054216; ＥＭＵＲＡ，　Ｔ．　ｅｔ　ａｌ．: ＩＮＴＥＲＮＡＴＩＯＮＡＬ　ＪＯＵＲＮＡＬ　ＯＦ　ＭＯＬＥＣＵＬＡＲ　ＭＥＤＩＣＩＮＥ Ｖｏｌ．１３，　Ｎｏ．２, 2004, ｐ．２４９-２５５ *
JPN6011054217; ＢＡＹＥＳ，　Ｍ．　ｅｔ　ａｌ．: Ｍｅｔｈｏｄｓ　Ｆｉｎｄ　Ｅｘｐ　Ｃｌｉｎ　Ｐｈａｒｍａｃｏｌ Ｖｏｌ．２６，　Ｎｏ．１, 2004, ｐ．５３-８４ *
JPN6012005376; 江村智博　他: 第６３回日本癌学会学術総会予稿集 , 2004, ｐ．４６６ *

Also Published As

Publication number Publication date
HUE033306T2 (hu) 2017-11-28
FR17C1028I2 (fr) 2018-11-02
TW200637562A (en) 2006-11-01
WO2006080327A1 (ja) 2006-08-03
KR20070104559A (ko) 2007-10-26
FR17C1028I1 (OSRAM) 2017-09-29
CY1119393T1 (el) 2018-02-14
NL300889I1 (nl) 2017-08-14
JPWO2006080327A1 (ja) 2008-06-19
LUC00036I2 (OSRAM) 2017-12-01
HUS1700032I1 (hu) 2017-09-28
CA2594713A1 (en) 2006-08-03
BE2017C028I2 (OSRAM) 2025-09-10
PT1849470T (pt) 2017-09-22
KR101468216B1 (ko) 2014-12-03
ES2630002T3 (es) 2017-08-17
TWI362265B (en) 2012-04-21
DK1849470T3 (en) 2017-08-14
PL1849470T3 (pl) 2017-11-30
RU2394581C2 (ru) 2010-07-20
SI1849470T2 (sl) 2024-05-31
NL300889I2 (nl) 2018-01-16
LT1849470T (lt) 2017-07-25
PL1849470T5 (pl) 2024-06-10
CY2017029I1 (el) 2018-02-14
LTC1849470I2 (lt) 2019-10-25
AU2006209547A1 (en) 2006-08-03
LTPA2017024I1 (lt) 2017-08-10
EP1849470A1 (en) 2007-10-31
EP1849470A4 (en) 2010-12-08
EP1849470B2 (en) 2024-03-20
CY2017029I2 (el) 2018-02-14
FI1849470T4 (fi) 2024-03-22
AU2006209547C1 (en) 2022-04-07
LUC00036I1 (OSRAM) 2017-10-02
SI1849470T1 (sl) 2017-10-30
DK1849470T4 (en) 2024-04-02
AU2006209547B2 (en) 2011-05-26
RU2007132181A (ru) 2009-03-10
ES2630002T5 (es) 2024-09-19
EP1849470B1 (en) 2017-06-21

Similar Documents

Publication Publication Date Title
JP5576591B2 (ja) α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤
USRE46284E1 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2025013684A (ja) 重度腎機能障害を有する癌患者に対する治療方法
EP2036903B1 (en) Potentiator of radiation therapy
US20090281105A1 (en) Radiotherapy enhancer
ES2644237T3 (es) Tratamiento de neurotoxicidad asociada a combinaciones de 5-FU o sus profármacos e inhibidores de DPD
EP2268287B1 (en) Dosage regimens of an antitumor agent comprising deoxycytidine derivative
TWI401085B (zh) Contains cytosine derivatives for continuous intravenous administration with anti-tumor agents
HK1115306A (en) ANTICANCER DRUG CONTAINING α, α, α-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR
WO2022014025A1 (ja) 血液がんの新規治療法及び新規治療剤
JPWO2012105486A1 (ja) １日１回隔日投与を特徴とするテガフール含有組成物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120426

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20120426

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120510

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20120515

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120622

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20120626

C141 Inquiry by the administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C141

Effective date: 20131217

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20131217

C54 Written response to inquiry

Free format text: JAPANESE INTERMEDIATE CODE: C54

Effective date: 20140217

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20140430

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20140430

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20140430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140514

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20140701

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20140701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140704

R150 Certificate of patent or registration of utility model

Ref document number: 5576591

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250